- Home
- CAPT vs BNR Comparison
CAPT vs BNR Comparison
Compare CAPT & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- BNR
- Stock Information
- Founded
- CAPT 2005
- BNR 2014
- Country
- CAPT South Korea
- BNR China
- Employees
- CAPT N/A
- BNR N/A
- Industry
- CAPT Blank Checks
- BNR Medical Specialities
- Sector
- CAPT Finance
- BNR Health Care
- Exchange
- CAPT Nasdaq
- BNR Nasdaq
- Market Cap
- CAPT 37.9M
- BNR 38.3M
- IPO Year
- CAPT N/A
- BNR 2020
- Fundamental
- Price
- CAPT $1.17
- BNR $8.71
- Analyst Decision
- CAPT
- BNR
- Analyst Count
- CAPT 0
- BNR 0
- Target Price
- CAPT N/A
- BNR N/A
- AVG Volume (30 Days)
- CAPT 155.8K
- BNR 51.7K
- Earning Date
- CAPT 01-01-0001
- BNR 09-08-2025
- Dividend Yield
- CAPT N/A
- BNR N/A
- EPS Growth
- CAPT N/A
- BNR N/A
- EPS
- CAPT N/A
- BNR N/A
- Revenue
- CAPT $17,389,944.00
- BNR $74,862,782.00
- Revenue This Year
- CAPT N/A
- BNR $136.32
- Revenue Next Year
- CAPT N/A
- BNR N/A
- P/E Ratio
- CAPT N/A
- BNR N/A
- Revenue Growth
- CAPT 84.70
- BNR 5.20
- 52 Week Low
- CAPT $0.37
- BNR $2.18
- 52 Week High
- CAPT $2.60
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- CAPT 47.02
- BNR 55.04
- Support Level
- CAPT $1.02
- BNR $8.30
- Resistance Level
- CAPT $1.16
- BNR $9.61
- Average True Range (ATR)
- CAPT 0.09
- BNR 0.64
- MACD
- CAPT 0.00
- BNR -0.12
- Stochastic Oscillator
- CAPT 59.52
- BNR 49.36
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.